Cormorant reports 4.35% stake in MoonLake
Cormorant Asset Management, LP and Bihua Chen report beneficial ownership of 3,205,433 Class A ordinary shares of MoonLake Immunotherapeutics, representing 4.35% of the class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Cormorant Asset Management, LP and Bihua Chen report beneficial ownership of 3,205,433 Class A ordinary shares of MoonLake Immunotherapeutics, representing 4.35% of the class. All reported shares are held with shared voting and dispositive power; neither reporting person has sole voting or dispositive power.
The ownership percentage is calculated using 73,615,396 Class A ordinary shares outstanding as of May 1, 2026, as stated in MoonLake’s quarterly report. The filing indicates ownership of 5 percent or less of this class of securities and includes customary disclaimers that the filing should not be construed as an admission of beneficial ownership for Section 13 purposes.
Key Figures
Key Terms
beneficial owner regulatory
Schedule 13G/A regulatory
percent of class financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of MoonLake Immunotherapeutics (MLTX) does Cormorant Asset Management currently report owning?
Do Cormorant Asset Management and Bihua Chen report owning more than 5% of MoonLake (MLTX)?
Who are the reporting persons in the MoonLake Immunotherapeutics (MLTX) Schedule 13G/A?
AI-generated analysis. How Rhea-AI works. Not financial advice.